294 related articles for article (PubMed ID: 22228398)
1. Inhibition of cathepsin K for treatment of osteoporosis.
Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
[TBL] [Abstract][Full Text] [Related]
2. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Watanabe R; Okazaki R
Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
[TBL] [Abstract][Full Text] [Related]
3. Potential role of odanacatib in the treatment of osteoporosis.
Ng KW
Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
5. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
6. [Cathepsin K antagonists: preclinical and clinical data].
Gamsjäger M; Resch H
Wien Med Wochenschr; 2015 Feb; 165(3-4):65-70. PubMed ID: 25572547
[TBL] [Abstract][Full Text] [Related]
7. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Lewiecki EM
IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
[TBL] [Abstract][Full Text] [Related]
8. Molecular and cellular basis of bone resorption.
Gruber R
Wien Med Wochenschr; 2015 Feb; 165(3-4):48-53. PubMed ID: 25223736
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.
Costa AG; Cusano NE; Silva BC; Cremers S; Bilezikian JP
Nat Rev Rheumatol; 2011 Jun; 7(8):447-56. PubMed ID: 21670768
[TBL] [Abstract][Full Text] [Related]
10. [Odanacatib (MK-0822)].
Nagase Y; Tanaka S
Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study.
Eastell R; Nagase S; Ohyama M; Small M; Sawyer J; Boonen S; Spector T; Kuwayama T; Deacon S
J Bone Miner Res; 2011 Jun; 26(6):1303-12. PubMed ID: 21312264
[TBL] [Abstract][Full Text] [Related]
13. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
14. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib.
Sims NA; Ng KW
Curr Osteoporos Rep; 2014 Mar; 12(1):98-106. PubMed ID: 24477416
[TBL] [Abstract][Full Text] [Related]
15. New targets for intervention in the treatment of postmenopausal osteoporosis.
Lewiecki EM
Nat Rev Rheumatol; 2011 Sep; 7(11):631-8. PubMed ID: 21931340
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis.
Helali AM; Iti FM; Mohamed IN
Curr Drug Targets; 2013 Dec; 14(13):1591-600. PubMed ID: 23957815
[TBL] [Abstract][Full Text] [Related]
17. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
[TBL] [Abstract][Full Text] [Related]
18. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
Tanaka M; Hashimoto Y; Hasegawa C; Deacon S; Eastell R
BMC Musculoskelet Disord; 2017 Jun; 18(1):267. PubMed ID: 28629344
[TBL] [Abstract][Full Text] [Related]
19. [Cathepsin K inhibitor: new therapy approach against osteoporosis. Pharmacological target in the osteoclast].
Aumiller J
MMW Fortschr Med; 2011 May; 153(19):16. PubMed ID: 21612088
[No Abstract] [Full Text] [Related]
20. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
Schultz TC; Valenzano JP; Verzella JL; Umland EM
Womens Health (Lond); 2015 Nov; 11(6):805-14. PubMed ID: 26344800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
